Jaragh-Alhadad Laila A, Ali Mayada S
Chemistry Department, Kuwait University, P. O. Box 5969, Safat 13060, Kuwait.
Saudi Pharm J. 2022 May;30(5):485-493. doi: 10.1016/j.jsps.2022.03.004. Epub 2022 Mar 10.
The repurposing strategy of converting nimesulide from an anti-fever drug to an anti-cancer agent by modifying its main structure targeting HSP27 is gaining great attention these days. The goal of this study focuses on synthesizing a new nimesulide derivative with new ligands that have biological anti-cancer activities in different cancer models using the in-vitro assay. Nimesulide derivative L1 was synthesized, characterized by 1H NMR, 13C NMR, FTIR, melting point, mass spectra, and TGA analysis. A single crystal was diffracted and showed colorless block group P-1. The results revealed that L1 demonstrates potent anti-cancer activity with lung (H292), ovarian (SKOV3), and breast (SKBR3) cancer cell lines in-vitro models with IC values below 8.8 µM.
通过修饰其靶向热休克蛋白27(HSP27)的主要结构,将尼美舒利从一种退烧药转变为抗癌剂的药物重新利用策略近来备受关注。本研究的目标聚焦于使用体外试验合成一种新的尼美舒利衍生物,该衍生物带有在不同癌症模型中具有生物抗癌活性的新配体。合成了尼美舒利衍生物L1,并通过1H核磁共振(NMR)、13C NMR、傅里叶变换红外光谱(FTIR)、熔点、质谱和热重分析(TGA)进行表征。对一个单晶进行了衍射,显示为无色块状,空间群为P-1。结果表明,在体外模型中,L1对肺癌(H292)、卵巢癌(SKOV3)和乳腺癌(SKBR3)细胞系表现出强大的抗癌活性,其半数抑制浓度(IC)值低于8.8微摩尔。